Lanean...
Dual Fulvestrant‐Trametinib Therapy in Recurrent Low‐Grade Serous Ovarian Cancer
Low‐grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK‐inhibitors displays synergism in preclinical ovarian cancer models, however....
Gorde:
| Argitaratua izan da: | Oncologist |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Inc.
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356701/ https://ncbi.nlm.nih.gov/pubmed/32369640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0101 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|